TREATMENT OF LOCALLY ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA WITH SEVERE COMORBIDITIES: A CASE REPORT

Ignas Lapeikis, Ieva Armonaitė, Donatas Petroska, Ugnius Mickys, Vincas Urbonas Abstract Advanced cutaneous squamous cell carcinoma (aCSCC) presents a significant therapeutic challenge, especially in patients with severe comorbidities that limit treatment options. Traditional treatments such as surgery and radiation may be unfeasible in frail patients, necessitating alternative therapies like immunotherapy. We present the case of…

IMMUNE MEDIATED SIDE EFFECTS OF PEMBROLIZUMAB AND NIVOLUMAB THERAPY: PATHOPHYSIOLOGY, GENETIC CONTRIBUTIONS AND CLINICAL SIGNIFICANCE

Karamello Halak, Yuseph Mohamed, Armantas Gintautas Abstract Pembrolizumab and nivolumab are examples of immune checkpoint inhibitors (ICIs) drugs that are cancer trea­ting drugs that reactivate antitumor immune responses. But they result in immune related side effects (irAEs) that are typically multisystemic and unpredictable. In additionally referring to advanced artificial intelligence (machine learning) for early detection…